This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.
- NXY-059 (Cerovive)Drug
- Allocation: Randomized
- Masking: Double-Blind
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Patients will be randomized to receive a one hour loading dose of NXY-059 followed by 71 hours of hourly infusion, or placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Overall recovery and recovery of motor function at 90 days as measured by the modified Rankin Scale.|
|Primary||Global disability on modified Rankin scale at 90 days.|
|Secondary||NIH stroke scale (termed "co-primary" in study protocol), Barthel Index, Stroke Impact Scale, EQ-5D all at 90 days, Safety outcomes.|
- AstraZeneca Lead